London, UK. - 5 September, 2007 - EyeforPharma is claiming that its latest conference in its portfolio of sales and marketing meetings is breaking the mould, to keep pace with pharma's dawning realisation its schizophrenic approach to dividing development and commercial down the middle is not maximizing profits.
The conference director says "It is apparent from speaking with people from leading pharma companies like Novartis, Pfizer, Merck, GlaxoSmithKlein and Astra Zeneca that the old order of things is disappearing, and they’re looking at how to move forward." So how can the Early Commercialisation, Lifecycle and Portfolio Management Congress held on 25th and 26th October in Barcelona, help pharma settle into a more integrated approach?
"This conference brings together all the elements pharma needs to address when aligning its development and commercial operations. It looks at building functioning teams to bridge the divide, how to ensure a smoother and more penetrating launch, how to handle a products lifecycle when it has reached the market…and what to do when it becomes challenged," says the conference director.
According to the brochure, available for download from www.eyeforpharma.com/drugvalue07/brochure.shtml, the most important topics addressed are increasing the speed and efficiency of the launch face, improving market access though engaging with key opinion leaders and improving on pricing strategies, and how to create the best multi-functional teams to achieve these aims. The other main section will deal with late-stage strategies for fending off generic competition; and how to best manage a complex portfolio.
"Value, this is the buzz word, everyone wants to know how to prove their drug is of value to patients and physicians, and I really believe at the end of the two days, the attendees will have a much clearer idea of how they can enhance their value propositions, and so achieve more market penetration."
Speakers at the conference include senior directors and VP's, coming from companies like Pfizer, GSK, Novartis and Wyeth. Again, the full speak line-up can be found in the brochure. The chairman of day one, Colin Ewan, Executive Director and Development Team Leader at Pfizer says "Our key question is: How do we ensure we get the maximum return out of the fewer and fewer breakthroughs coming from the lab?," a question he hopes will be answered by "listening to hundreds of years of combined marketing experience."
EyeforPharma is currently offering discounts to those who secure their place at the Summit early, with €200 knocked off the price of tickets to anyone registering before September 28th.
Further updates, full information on presentations and speakers, and details on ticket options can all be found by downloading the brochure at www.eyeforpharma.com/drugvalue07/brochure.shtml
EyeforPharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. EyeforPharma also provides a fortnightly newsletter to over 11 thousand leading executives from every major pharmaceutical company in the industry, and of course consultants, sponsors and academics as well. The EyeforPharma wiki, launched last month, highlights our dedication to improving the communication between people in the industry and furthering learning and development within it. Please visit www.eyeforpharma.com to find out more about us.
Global Event Director
+44 (0) 207 3757 201
US Toll Free: 1 800 814 3459 ext. 323
Issuers of news releases, not Targetwire, are solely responsible for the accuracy of the content.